Tweet
Vaccine. 2016 Jul 26. pii: S0264-410X(16)30591-6. doi: 10.1016/j.vaccine.2016.07.018. [Epub ahead of print]
High-dose influenza vaccine favors acute plasmablast responses rather than long-term cellular responses.
Kim JH1, Talbot HK2, Mishina M3, Zhu Y4, Chen J1, Cao W1, Reber AJ1, Griffin MR4, Shay DK1, Spencer SM1, Sambhara S1.
Author information
Abstract
High-dose (HD) influenza vaccine shows improved relative efficacy against influenza disease compared to standard-dose (SD) vaccine in individuals ⩾65years. This has been partially credited to superior serological responses, but a comprehensive understanding of cell-mediated immunity (CMI) of HD vaccine remains lacking. In the current study, a total of 105 participants were randomly administered HD or SD vaccine and were evaluated for serological responses. Subsets of the group (n=12-26 per group) were evaluated for B and T cell responses at days 0, 7, 14 and 28 post-vaccination by flow cytometry or ELISPOT assay. HD vaccine elicited significantly higher hemagglutination inhibition (HI) titers than SD vaccine at d28, but comparable titers at d365 post-vaccination. HD vaccine also elicited higher vaccine-specific plasmablast responses at d7 post-vaccination than SD vaccine. However, long-lived memory B cell induction, cytokine-secreting T cell responses and persistence of serological memory were comparable regardless of vaccine dose. More strategies other than increased Ag amount may be needed to improve CMI in older adults.
TRIAL REGISTRATION:
ClinicalTrials.gov NCT 01189123.
Copyright ? 2016. Published by Elsevier Ltd.
KEYWORDS:
Cell-mediated immunity; High-dose influenza vaccine; Older adults; Plasmablast response
PMID: 27473306 DOI: 10.1016/j.vaccine.2016.07.018
[PubMed - as supplied by publisher]
High-dose influenza vaccine favors acute plasmablast responses rather than long-term cellular responses.
Kim JH1, Talbot HK2, Mishina M3, Zhu Y4, Chen J1, Cao W1, Reber AJ1, Griffin MR4, Shay DK1, Spencer SM1, Sambhara S1.
Author information
Abstract
High-dose (HD) influenza vaccine shows improved relative efficacy against influenza disease compared to standard-dose (SD) vaccine in individuals ⩾65years. This has been partially credited to superior serological responses, but a comprehensive understanding of cell-mediated immunity (CMI) of HD vaccine remains lacking. In the current study, a total of 105 participants were randomly administered HD or SD vaccine and were evaluated for serological responses. Subsets of the group (n=12-26 per group) were evaluated for B and T cell responses at days 0, 7, 14 and 28 post-vaccination by flow cytometry or ELISPOT assay. HD vaccine elicited significantly higher hemagglutination inhibition (HI) titers than SD vaccine at d28, but comparable titers at d365 post-vaccination. HD vaccine also elicited higher vaccine-specific plasmablast responses at d7 post-vaccination than SD vaccine. However, long-lived memory B cell induction, cytokine-secreting T cell responses and persistence of serological memory were comparable regardless of vaccine dose. More strategies other than increased Ag amount may be needed to improve CMI in older adults.
TRIAL REGISTRATION:
ClinicalTrials.gov NCT 01189123.
Copyright ? 2016. Published by Elsevier Ltd.
KEYWORDS:
Cell-mediated immunity; High-dose influenza vaccine; Older adults; Plasmablast response
PMID: 27473306 DOI: 10.1016/j.vaccine.2016.07.018
[PubMed - as supplied by publisher]